To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Europe | European ＆ international partnerships | Antibiotics | Biodetection | Biotechnology
Tool for a fast, simple, affordable and direct detection of β-lactamases in clinical samples
The BL DetecTool project, coordinated by Hervé Volland (LERI/SPI), aims to develop rapid antibiotic resistance detection tests. The system developed by BL-DetectTool uses a testing strip and a device that can be produced by 3D printer to detect the presence of drug resistant bacteria. This simple user-friendly innovation gives hospitals a powerful weapon in the fight against antimicrobial resistance, one of the greatest threats to public health that we face today.
Antimicrobial resistance has a high impact on public health and the economy. Every year, 700 000 people die worldwide because of infections caused by multidrug-resistant pathogens, and the costs for the treatment of these infections is estimated at €1.5 billion annually, in Europe alone. The BL-DetecTool is a promising innovation aimed at detecting drug resistant bacteria by identifying broad-spectrum β-lactamases (called ESBL and carbapenemases), directly from the patient's sample.The system developed by BL-DetectTool uses a testing strip and a device that can be produced by 3D printer to detect the presence of drug resistant bacteria. This simple user-friendly innovation gives hospitals a powerful weapon in the fight against antimicrobial resistance, one of the greatest threats to public health that we face today.This project involves: three hospitals, ISGlobal (Spain); APHP (France); Semmelweis University (Hungary), which validate the BL-DetecTool and optimise operating procedures, one research coordinating organization, CEA (France), which designed and produces the BL-DetecTool, one business school, IESE (Spain), which establishes the business plan, one company, NG Biotech (France), which is involved in the production of the BL-DetecTool, and will market it when it is made commercially available.Rapid detection and identification of β-lactamases-producing bacteria is essential to prevent further spread of these dangerous bacteria and to provide appropriate antimicrobial therapy. BL-DectecTool seeks to optimise and validate a new detection system that is the first to allow fast, affordable, user-friendly and direct detection of β-lactamases in clinical samples. The innovation consists of a β-lactamases detection strip, which is enclosed in a plastic device. The device, produced by 3D printing, carries out the sample treatment. It is smaller and more portable than current detection procedures, and it provides results much more quickly – in 30 minutes instead of 16 hours or more – and more affordably.
Through this project, the devices will be optimised and validated with real clinical samples. The operational procedures will be improved to fit with clinical habits and analytical specifications (sensitivity, specificity and reproducibility). At the end of the project, a business concept will be established and training tools for end-users will be provided to accelerate the industrial transfer and its implementation in care facilities. EIT Health funding of this project boosts the development, validation and launch to the market of this badly needed rapid diagnostic tool.
CONTACT : Hervé Volland (email@example.com)
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.